Evotec SE stock (DE0005664809): Recent price gains signal short-term momentum

Evotec SE shares rose 0.386% to 5.20€ on May 11, 2026, with analysts upgrading to a Buy rating amid positive short-term signals for the German biotech firm listed on Nasdaq.

Evotec SE, a global drug discovery partner, saw its stock gain 0.386% on May 11, 2026, closing at 5.20€ on the German exchange, according to StockInvest.us as of 05/11/2026. The Nasdaq-listed shares (EVO) traded around $4.80 recently, reflecting volatility in the biotech sector. This modest uptick comes as technical analysis highlights buying opportunities near support levels.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Healthcare / Drug Manufacturers - Specialty & Generic
• Headquarters/country: Hamburg, Germany
• Core markets: Global, with focus on pharma partnerships
• Key revenue drivers: Drug discovery services, R&D programs
• Home exchange/listing venue: Nasdaq (EVO), Xetra (EVT.DE)
• Trading currency: USD (Nasdaq), EUR (Germany)

Evotec SE: core business model

Evotec SE provides integrated drug discovery and development solutions to pharmaceutical companies, biotech firms, and academic institutions worldwide. The company operates through standalone services and strategic alliances, targeting areas like oncology, neurology, and infectious diseases, per its profile on Morningstar as of 05/2026. With headquarters in Hamburg, Evotec employs over 4,500 people and focuses on accelerating innovation via AI-driven platforms and partnerships.

This model generates revenue from milestone payments, royalties, and service fees. Evotec's Nasdaq listing (EVO) offers US investors exposure to European biotech expertise, bridging transatlantic R&D needs in a sector critical to US healthcare advancements.

Main revenue and product drivers for Evotec SE

Key drivers include partnerships with big pharma for CNS disorders, diabetes, and oncology programs. The firm's technology platforms, such as phenotypic screening and AI analytics, support end-to-end discovery, as detailed on MarketBeat as of 05/2026. Recent activity includes events like the European Cancer Immunotherapy Meeting on May 12, 2026, highlighting immunotherapy focus.

Revenue is bolstered by a pipeline of over 200 programs, with US market relevance through collaborations impacting American drug pipelines and clinical trials.

Why Evotec SE matters for US investors

Listed on Nasdaq as EVO, Evotec provides US retail investors direct access to a leading German biotech without ADR complexities. Its partnerships with US-based pharmas expose it to the world's largest healthcare market, where biotech spending drives innovation, according to sector data.

Industry trends and competitive position

The drug discovery outsourcing market is expanding, with firms like Evotec benefiting from Big Pharma's shift to partnerships amid rising R&D costs. Evotec's small-cap status ($1.09B market cap) positions it agilely against giants like Lonza or WuXi AppTec, per MarketBeat as of 05/2026.

Conclusion

Evotec SE's recent 0.386% price gain to 5.20€ on May 11, 2026, alongside a Buy upgrade from technical analysis, underscores short-term optimism for this Nasdaq-listed biotech. With a focus on high-demand therapeutic areas and upcoming industry events, the stock remains tied to partnership milestones. US investors gain exposure to global drug discovery trends through EVO shares, though biotech volatility persists.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.